Skip to main content
Erschienen in: Wiener klinische Wochenschrift 17-18/2021

20.04.2021 | perspective

Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients

verfasst von: Antonio Vitiello, Francesco Ferrara

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2021

Einloggen, um Zugang zu erhalten

Excerpt

Coronaviruses (CoV) are a large family of viruses that cause illnesses ranging from the common cold to more severe diseases. A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. The new virus was subsequently named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease caused by the virus is coronavirus disease 2019 (COVID-19). The new coronavirus SARS-CoV‑2 (COVID-19) is responsible for the current global pandemic [1]. In December 2020, vaccinations began in Europe. To date, forms of treatment are experimental [2]. The COVID-19 infection has caused 2 million deaths [3]. The infection is described in three phases: the first asymptomatic or slightly symptomatic, the second moderately severe characterized by a pulmonary inflammatory state, the third very severe characterized by a generalized inflammatory state affecting all tissues causing multiorgan dysfunction. In the more severe stages of infection, COVID-19 lung lesions are characterized by diffuse alveolar damage with irregular inflammatory cellular infiltration [4, 5].The literature data not only identify COVID-19 viral infections as a respiratory disease, but in more severe cases there may be involvement of other organs, such as the heart and liver, contributing to the development of serious complications [6]. Pharmacological treatment of the infection involves the use of antivirals, anticoagulants and immunomodulants [710]. In the most severe stages of infection, a generalized inflammatory state induced by a cytokine storm results in multiorgan dysfunction and tissue injury. The SARS-CoV‑2 penetrates cells using the S protein through the angiotensin-converting enzyme receptor 2 (ACE-2) widely present in respiratory mucosa epithelial cells and other tissues. ACE‑2 is also a conversion enzyme with a key role in the renin-angiotensin system (RAS) [11]. …
Literatur
1.
Zurück zum Zitat McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Public health—seattle and king county, evergreenhealth, and CDC COVID-19 investigation team. Epidemiology of Covid-19 in a long-term care facility in king county, washington. N Engl J Med. 2020;382(21):2005–11. https://doi.org/10.1056/NEJMoa2005412.CrossRefPubMed McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Public health—seattle and king county, evergreenhealth, and CDC COVID-19 investigation team. Epidemiology of Covid-19 in a long-term care facility in king county, washington. N Engl J Med. 2020;382(21):2005–11. https://​doi.​org/​10.​1056/​NEJMoa2005412.CrossRefPubMed
4.
Zurück zum Zitat Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of Coronavirus. In: StatPearls. 2020. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of Coronavirus. In: StatPearls. 2020.
17.
Zurück zum Zitat Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV‑2 pneumonia. Ital J Med. 2020;14(2):88–94. Vitiello A, Ferrara F, Pelliccia C, Granata G, La Porta R. Cytokine storm and colchicine potential role in fighting SARS-CoV‑2 pneumonia. Ital J Med. 2020;14(2):88–94.
18.
Zurück zum Zitat Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;76(11):1615–1618. https://doi.org/10.1007/s00228-020-02947-4. Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol. 2020;76(11):1615–1618. https://​doi.​org/​10.​1007/​s00228-020-02947-4.
30.
32.
Zurück zum Zitat Bükülmez H, Khan F, Bartels CF, Murakami S, Ortiz-Lopez A, Sattar A, et al. Protective effects of C‑type natriuretic peptide on linear growth and articular cartilage integrity in a mouse model of inflammatory arthritis. Arthritis Rheumatol. 2014;66(1):78–89. https://doi.org/10.1002/art.38199.CrossRefPubMed Bükülmez H, Khan F, Bartels CF, Murakami S, Ortiz-Lopez A, Sattar A, et al. Protective effects of C‑type natriuretic peptide on linear growth and articular cartilage integrity in a mouse model of inflammatory arthritis. Arthritis Rheumatol. 2014;66(1):78–89. https://​doi.​org/​10.​1002/​art.​38199.CrossRefPubMed
34.
35.
Zurück zum Zitat Li ZQ, Liu YL, Li G, Li B, Liu Y, Li XF, et al. Inhibitory effects of C‑type natriuretic peptide on the differentiation of cardiac fibroblasts, and secretion of monocyte chemoattractant protein‑1 and plasminogen activator inhibitor‑1. Mol Med Rep. 2015;11(1):159–65. https://doi.org/10.3892/mmr.2014.2763.CrossRefPubMed Li ZQ, Liu YL, Li G, Li B, Liu Y, Li XF, et al. Inhibitory effects of C‑type natriuretic peptide on the differentiation of cardiac fibroblasts, and secretion of monocyte chemoattractant protein‑1 and plasminogen activator inhibitor‑1. Mol Med Rep. 2015;11(1):159–65. https://​doi.​org/​10.​3892/​mmr.​2014.​2763.CrossRefPubMed
46.
Zurück zum Zitat Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy. Vasc Health Risk Manag. 2007;3:125–37.PubMedPubMedCentral Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy. Vasc Health Risk Manag. 2007;3:125–37.PubMedPubMedCentral
48.
Zurück zum Zitat Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22(6):957–66. https://doi.org/10.1002/ejhf.1871.CrossRefPubMed Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22(6):957–66. https://​doi.​org/​10.​1002/​ejhf.​1871.CrossRefPubMed
52.
Zurück zum Zitat Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.CrossRefPubMedPubMedCentral Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.CrossRefPubMedPubMedCentral
54.
Metadaten
Titel
Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients
verfasst von
Antonio Vitiello
Francesco Ferrara
Publikationsdatum
20.04.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 17-18/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01855-6

Weitere Artikel der Ausgabe 17-18/2021

Wiener klinische Wochenschrift 17-18/2021 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps